Therefore, empowering clinicians with evidence-based insights that once-weekly insulin icodec has achieved superior glycemic control compared to once-daily basal insulin in some phase 3 trials, with no significant difference in the occurrence of hypoglycemia [72], can help them make informed decisions about the best choice of treatment for their patients in the near future (Fig. 3). The gene discussed is INS; the disease is Hypoglycemia.